Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 108, Issue 7, Pages djw003
Publisher
Oxford University Press (OUP)
Online
2016-03-05
DOI
10.1093/jnci/djw003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU
- (2015) Rena M. Conti et al. ANNALS OF HEMATOLOGY
- Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
- (2014) N. P. Shah et al. BLOOD
- The Ethics Of ‘Fail First’: Guidelines And Practical Scenarios For Step Therapy Coverage Policies
- (2014) Rahul K. Nayak et al. HEALTH AFFAIRS
- Chronic Myeloid Leukemia–Transplantation in the Tyrosine Kinase Era
- (2014) Andrew J. Innes et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Clinical efficacy of generic imatinib
- (2014) Mario L de Lemos et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- High Cancer Drug Prices in the United States: Reasons and Proposed Solutions
- (2014) Hagop Kantarjian et al. Journal of Oncology Practice
- Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States
- (2013) Rochelle P. Walensky et al. ANNALS OF INTERNAL MEDICINE
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
- (2013) T. P. Hughes et al. BLOOD
- Measuring the symptom burden associated with the treatment of chronic myeloid leukemia
- (2013) L. A. Williams et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?
- (2013) F.-X. Mahon et al. CLINICAL CANCER RESEARCH
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
- (2013) Philippe Rousselot et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
- (2013) Stacie B. Dusetzina et al. JOURNAL OF CLINICAL ONCOLOGY
- Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia
- (2013) Annie Guérin et al. JOURNAL OF MEDICAL ECONOMICS
- A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study
- (2013) Suzanne Dunne et al. BMC Pharmacology & Toxicology
- Costs and Cost-Effectiveness of Hematopoietic Cell Transplantation
- (2012) Jaime M. Preussler et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
- (2012) E Jabbour et al. LEUKEMIA
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
- (2011) F. Efficace et al. BLOOD
- Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
- (2011) A. R. Ibrahim et al. BLOOD
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
- (2010) T. P. Hughes et al. BLOOD
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
- (2009) L. Noens et al. BLOOD
- Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries
- (2009) Pierre Emmanuel Paradis et al. CURRENT MEDICAL RESEARCH AND OPINION
- A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia
- (2009) Shelagh M. Szabo et al. VALUE IN HEALTH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now